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Abstract: Antibody-mediated rejection (AMR) has been identified as a significant form of acute allograft
dysfunction in lung transplantation. The development of consensus diagnostic criteria has created a uniform
definition of AMR; however, significant limitations of these criteria have been identified. Treatment
modalities for AMR have been adapted from other areas of medicine and data on the effectiveness of
these therapies in AMR are limited. AMR is often refractory to these therapies, and graft failure and death
are common. AMR is associated with increased rates of chronic lung allograft dysfunction (CLAD) and
poor long-term survival. In this review, we discuss the history of AMR and describe known mechanisms,
application of the consensus diagnostic criteria, data for current treatment strategies, and long-term
outcomes. In addition, we highlight current gaps in knowledge, ongoing research, and future directions
to address these gaps. Promising diagnostic techniques are actively being investigated that may allow for
early detection and treatment of AMR. We conclude that further investigation is required to identify and
define chronic and subclinical AMR, and head-to-head comparisons of currently used treatment protocols
are necessary to identify an optimal treatment approach. Gaps in knowledge regarding the epidemiology,
mechanisms, diagnosis, and treatment of AMR continue to exist and future research should focus on these
aspects.
Keywords: Lung transplantation; graft rejection; allograft tolerance; acute lung injury; complement component;
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rituximab; eculizumab; outcome assessment
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Introduction
Lung transplantation is the ultimate treatment for selected
patients with end-stage lung disease. While advances in
surgical technique have improved early survival, long
term outcomes remain disappointing, and the median
survival after transplantation in the most recent era is
6.5 years (1). Chronic lung allograft dysfunction (CLAD)
is the leading cause of death beyond the first year after
lung transplantation and has emerged as the main barrier
to better long-term outcomes (1). Antibody-mediated
rejection (AMR) has been increasingly recognized after
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lung transplantation and has been consistently identified as
a significant cause of morbidity, CLAD, and graft failure
(2-7). Here, we present a review of our current
understanding of AMR and discuss ongoing research and
future directions to further our understanding of AMR and
improve the management of this serious complication after
lung transplantation.
History
Our understanding of AMR in lung transplantation
was historically limited to hyperacute rejection, which
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occurs when preformed donor-specific antibodies (DSA)
bind to mismatched human leukocyte antigens (HLA)
(8,9). Patients developed significant and often fatal
graft failure intra-operatively or in the immediate postoperative period with hemorrhagic pulmonary edema
and diffuse pulmonary infiltrates on imaging studies
(8,10,11). Severe graft dysfunction occurred in spite of
intensive immunosuppression targeting T-cell proliferation
and activity, which suggested a role for humoral
immunity in precipitating this response. Typically, these
patients were found to have DSA and a positive direct
lymphocytotoxicity crossmatch. Further investigation
found that allosensitization was associated with worse
survival after transplantation unless the reactive HLA were
avoided in a prospective donor (8-10,12,13). Case reports of
hyperacute rejection suggested the need for standardization
of pretransplant crossmatching (6,8). Although hyperacute
rejection has become rare in the current era because of
improved HLA antibody detection assays, it illustrates that
HLA antibodies can cause fulminant graft failure and that
the capillary endothelium is the focal point of injury.
Over time, cases occurring later after transplantation
were recognized and our understanding of acute AMR
began to evolve. Badesch and colleagues presented a case
series of 5 patients with pulmonary capillaritis ranging
from 3 weeks to months after transplant (14). In this
series, all patients presented with alveolar hemorrhage
and graft failure with temporary improvement in graft
function with intensification of immunosuppression and
plasmapheresis (14). They postulated a humoral
immunologic response, though testing for DSA or
antibody binding on pathologic specimens was not
performed (14). Magro and colleagues described the
histologic features of 22 lung transplant recipients who
developed pulmonary capillaritis ranging from 1 to 33
months after transplantation (15). They described septal
capillary necrosis with staining positive for complement
deposition (C1q, C3, and C4d) and immunoglobulin
G (IgG) (15). All patients were tested and found to
be negative for panel-reactive antibodies (PRA) both
before transplantation and at the time of acute rejection;
however, the use of older and less sensitive assays limits
the significance of this finding (11,15). Treatment with
plasmapheresis showed improvement in graft function and
a decrease in post-pheresis capillary injury and complement
deposition (15). Witt and colleagues detailed a series of 21
patients with acute AMR (3). In this series, all patients had
clinical allograft dysfunction, DSA, histology of acute lung
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injury, and capillary endothelial C4d deposition (3). Six
patients (29%) died of refractory AMR, while 15 survived
to hospital discharge (3). One patient had a diagnosis of
bronchiolitis obliterans syndrome (BOS) at AMR diagnosis,
and 13 of the remaining 14 survivors developed CLAD
during follow up (3). Overall 15/21 (71%) patients died
during the study period and median survival after diagnosis
of AMR was 593 days (3). These studies established
the basis for further investigation of the diagnosis and
management of acute AMR.
Pathogenesis
Mechanisms of AMR were initially elucidated by
investigations in transplantation of other solid organs,
especially in kidney transplantation (16,17). This work has
shown hyperacute, acute, and chronic forms of AMR in
which activation of allospecific B-cells and plasma cells leads
to formation of DSA that bind to HLA on the endothelium
of vessels within the allograft (6,16,18,19). Antibody
biding leads to complement dependent and independent
recruitment of immune cells leading to graft dysfunction
and tissue injury (6,16,18-20).
DSA were first identified in renal transplant recipients
in the 1960s and were postulated to be the underlying
cause for immediate graft failure. Subsequent investigation
confirmed that the presence of preformed antibodies
in recipient sera was associated with a high rate of graft
failure. These failures led to the use of a crossmatch of the
recipients serum with donor cells and assays to identify
DSA (21-23). Since that time, highly sensitive and specific
solid phase assays for the identification of HLA antibodies
have been developed (6,16,24). Recipients may have preexisting HLA antibodies (as a result of prior sensitizing
events such as blood transfusion, pregnancy, or previous
organ transplantation) or may develop HLA antibodies de
novo after transplantation (6,9,11,12,17). Recipients may
have antibodies to MHC class I antigens (HLA-A, HLA-B,
or HLA-C) which are present on all nucleated cells, or to
MHC class II antigens (HLA-DQ, HLA-DR, HLA-DP)
which are present on antigen presenting cells (APCs) (25).
Notably, pro-inflammatory cytokines have been shown
to induce the expression of class II HLA on pulmonary
endothelial cells (26,27). Recipients may also develop
antibodies to non-HLA antigens (allo- or auto-antigens);
however, no highly sensitive assays have been developed to
detect such antibodies to date (5,25,28).
Complement-binding DSA are associated with worse
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outcomes in kidney and heart transplant recipients,
and preliminary work echoes these findings in lung
transplantation (3,29,30). DSA bind antigens on donor
endothelial cells with activation of the classical complement
cascade and formation of the membrane attack complex
(MAC). The MAC causes endothelial cell injury with
exposure of the basement membrane and activation of the
coagulation cascade leading to thrombosis and infarction.
Moreover, complement factors 3a and 5a (C3a and C5a)
are chemokines that attract immune cells to the allograft
propagating inflammation and graft injury (11,15,31).
Importantly, not all DSA bind and activate complement, and
DSA-associated complement-independent mechanisms of
allograft injury have been studied in vitro and in vivo models
of solid organ transplantation (6,16,31-36). Proposed
mechanisms include activation of signaling cascades that
lead to endothelial and smooth muscle cell proliferation,
release of inflammatory cytokines and chemokines, and
von Willebrand factor (vWF) and P-selectin mediated
platelet activation (6,11,31-36). These findings not only
implicate DSA in complement-independent mechanisms of
AMR, but also suggest a role for DSA in chronic allograft
rejection (6,11,31,36,37).
Recent work by Li and colleagues has shown that
the immunopathology of AMR may be different in
lung allografts compared to allografts of other solid
organs (38). This group utilized a mouse lung retransplantation model and found that tolerant pulmonary
allografts developed bronchus-associated lymphoid tissue
(BALT) (38). Suppression of FoxP3 + regulatory T-cells
in this model led to the absence of BALT formation
and development of AMR (38). These findings suggest
that regulatory T-cells residing in BALT of pulmonary
allografts suppress B-cell activation locally and that antigen
presentation can occur within the allograft (38). These
findings are contrary to models of AMR in other solid
organ transplants where humoral responses are regulated
peripherally (38). This is further echoed by the differences
noted in the diagnosis, management, and outcomes of
AMR in lung allografts as compared to other solid organ
transplants (3-6,31,39,40).
Clinical manifestations and diagnosis
The International Society for Heart and Lung
Transplantation (ISHLT) convened a working group in
2016 to create a uniform definition of AMR (6). The
definition was largely based on experience in kidney
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and heart transplantation. According to this definition,
a definite diagnosis of AMR requires the presence of
allograft dysfunction, DSA, characteristic lung pathology,
complement factor 4d (C4d) deposition on capillary
endothelium, and the exclusion of alternate etiologies
of graft dysfunction (6). The working group recognized
potential shortcomings of these diagnostic criteria and
proposed a qualitative assessment of the certainty of the
diagnosis as being definite, probable, or possible based
on the number of criteria met (6). Graft dysfunction
associated with clinical AMR may range from fulminant
respiratory failure to asymptomatic dysfunction identified
on surveillance spirometry (6). Chronic AMR is a defined
form of rejection in kidney transplantation and has been
suggested in both heart and lung transplantation, but
there is no specific definition in lung transplantation
(16,17). Although investigations in lung transplantation
have shown an association between DSA and CLAD,
which most commonly presents as BOS, it is unclear
if such cases represent chronic AMR as these are
typically indistinguishable from cases that lack DSA
(2-4,6,9,11,37,39,41). Furthermore, depletion of DSA has
been associated with greater freedom from BOS (37). Roux
and colleagues reviewed 206 transplanted patients and found
that restrictive allograft syndrome (RAS) was only present
in patients who had DSA and developed AMR, while BOS
or mixed CLAD (BOS and RAS) were found in all groups
of patients regardless of presence of DSA or AMR (5). It
is appealing to consider whether RAS is a form of chronic
AMR, but definitive data have been lacking to date. The
ISHLT working group also recognized sub-clinical AMR as
the detection of histologic criteria of AMR in the absence
of graft dysfunction (6). Chronic and sub-clinical AMR
remain poorly described in lung transplantation and further
investigation is required to identify the significance of these
diagnoses.
The presence of DSA is requisite for a diagnosis of
AMR based on these criteria; however, only a minority
of patients with DSA go on to develop AMR (11,16,42).
Furthermore, detection of DSA can be missed due to phasic
release or absence of the antigen on the screening assay (6).
Highly sensitive solid phase assays for DSA provide mean
fluorescence intensity (MFI) values which do not always
accurately depict antibody strength (43). Specificity can be
improved with assays for binding of complement factor 1q
(C1q) but this may decrease sensitivity (43).
Multiple pathologic findings of AMR have been
described in lung allografts including capillary
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inflammation, endothelialitis, and acute lung injury
(9,44,45). The earliest report of hyperacute AMR of a
lung allograft noted the presence of acute lung injury
with hyaline membrane formation along with alveolar
edema and hemorrhage (8). Subsequent reports described
pulmonary capillaritis and neutrophilic infiltration as the
hallmark findings of pulmonary AMR (46). However,
further investigation has shown that neutrophils are just
one of the many cell types that are part of the spectrum of
microvascular inflammation and the absence of neutrophil
infiltration or capillaritis should not rule out AMR
(31,47,48). Neutrophilic capillaritis is nonspecific and has
been associated with graft dysfunction in the absence of
AMR (41,42,48). Furthermore, the presence of capillaritis
may be obscured by severe acute lung injury. Acute lung
injury may present as alveolar edema, alveolar hemorrhage,
hyaline membrane formation with diffuse alveolar damage,
fibrin deposition, intravascular platelet or fibrin thrombi,
or arteriolar fibrinoid necrosis (2,47,49). These findings
suggest that the histopathologic findings of AMR are
nonspecific and underscore the need for a multidisciplinary
approach to diagnosis.
Staining for complement split product C4d is the most
controversial criterion for the diagnosis of AMR (50).
Complement split products bind to endothelial cells noncovalently and are subsequently inactivated by membrane
cofactor protein, decay accelerating factor, and CD59 (51).
However, unlike other complement split products, C4d
binds the endothelium covalently via a thioester bond (51).
This covalent bond is stable, resistant to shedding, and
allows C4d to be detected long after other complement
split products have been inactivated (51). While C4d
staining gained popularity in diagnosis of AMR in renal
allografts and provides direct evidence of the immunepathologic effect of antibodies, it has proven to be a
challenging criterion in AMR of lung transplant recipients
(5,6,11,44). C4d staining has been shown to be positive in
pathology other than AMR such as ischemia-reperfusion
injury, high grade ACR, and infection (5,6). Furthermore,
C4d has been shown to be positive in only a minority of
cases of AMR in lung transplant recipients, giving rise to
“C4d-negative” AMR (2-4,52). It remains unclear if C4dnegative AMR represents a unique form of AMR due to
complement-independent pathways or if this is related to
limitations of staining or interpretation of specimens (52).
Finally, Roden and colleagues found poor correlation
between immunofluorescence and immunohistochemical
testing for C4d, and poor inter-reader reliability among
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pathologists (50).
Treatment
Treatment options for AMR in lung transplantation
have been adapted from other areas of medicine. Data
supporting the use of individual interventions are sparse and
no randomized clinical trials or head-to-head comparisons
have been undertaken, making it difficult to draw
conclusions about the efficacy of any single intervention
(Table 1). Treatment regimens generally consist of multiple
interventions and are individualized based on clinical course
and response to other therapies.
Corticosteroids
Corticosteroids inhibit the early steps of the acute
inflammatory response by altering the transcription of
numerous genes in leukocytes (53). These genes affect
leukocyte maturation, differentiation, distribution, and
trafficking (53). High-dose corticosteroids are utilized in
treatment regimens for AMR across kidney, heart, and lung
transplantation (4,16,54). Astor and colleagues presented
a retrospective review of 40 patients of whom only 43%
responded to steroid monotherapy (46). Steroid resistance
was identified as a marker for AMR in early reports (14,46).
Plasmapheresis
Plasmapheresis separates and discards plasma from whole
blood replacing it with fresh frozen plasma or albumin and,
therefore, eliminates circulating antibodies. In addition to
reducing DSA, plasmapheresis has been shown to decrease
deposition of complement split products (15). While
plasmapheresis depletes circulating antibody, it does not
decrease antibody production and can result in a rebound
increase in antibody production. Due to its ability to eliminate
circulating antibody, plasmapheresis gained popularity
for the treatment of AMR in kidney transplantation (55).
Retrospective studies in AMR of lung allografts have
found variable benefit with use of plasmapheresis
(4,7,8,10,12,14,15,46,56). These results are challenging to
interpret, as plasmapheresis is rarely used as monotherapy and
plasmapheresis protocols differ among studies.
Intravenous immunoglobulin (IVIG)
IVIG has traditionally been used in the treatment of
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Table 1 Treatment modalities for AMR in lung transplantation
Treatment

Mechanism

References

Corticosteroids

Alter transcription of genes in leukocytes

(4,14,16,46,53,54)

Plasmapheresis

Elimination of circulating antibodies; decrease deposition of
complement split products

(4,7,8,10,12,14,15,46,55,56)

Intravenous Immunoglobulin
(IVIG)

Unclear; proposed mechanisms include modulation of Fcγ receptor,
inactivation of DSA, downregulation of B-cells, inhibition of
complement cascade, reduction of MHC class II expression

(4,57-59)

Rituximab

Depletion of circulating B-cells

(37,60)

Proteasome Inhibition

Plasma cell apoptosis

(61-63)

Complement Inhibition

Inhibition of formation of the membrane attack complex

(10,64)

AMR, antibody-mediated rejection; DSA, donor-specific antibodies.

immunodeficiency syndromes and passive immunity but
also has applications in immune mediated conditions such as
Guillan-Barré syndrome, immune thrombocytopenia (ITP),
and myasthenia gravis. IVIG has become a standard part of
protocols for treatment of AMR, but the precise mechanism
of action is unclear (57). Proposed mechanisms include
modulation of expression and function of the Fcγ receptor,
inactivation of DSA, downregulation of B-cells, inhibition
of the complement cascade and the cytokine network, and
reduction of MHC class II antigen expression (57,58). IVIG
may be used as monotherapy but is more commonly used
in conjunction with plasmapheresis and/or corticosteroids
(57,59). Dosing of IVIG has been variable with ranges from
100–2,000 mg/kg (4,57).
Rituximab
Rituximab is an anti-CD20 antibody that binds to preB-cells and mature B-lymphocytes in circulation, lymph
nodes, and bone marrow and induces apoptosis and cell
lysis (60). While rituximab depletes circulating B-cells,
it has no known effect on plasma cells that may already
be producing antibody. Rituximab has been studied in
the treatment of B-cell neoplasms and autoimmune
conditions (60). Rituximab plus IVIG was found to improve
survival over IVIG alone in a protocol to preemptively
treat DSA; however, groups were not randomized and no
difference in rejection rates was found (37). Indeed, data for
the treatment of AMR with rituximab are sparse.
Proteasome inhibition
Proteasomes degrade misfolded and ubiquitinated proteins.
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Bortezomib and carfilzomib bind and inhibit proteasomes
in plasma cells allowing the accumulation of these proteins
and leading to plasma cell apoptosis (61-63). Proteasome
inhibitors have largely been studied in the treatment of
multiple myeloma (61,62). Observational studies have
shown that treatment with proteasome inhibitors in AMR
depletes DSA and improves allograft function (61,62), but
no head-to-head comparisons or clinical trials have been
published to date.
Complement inhibition
Eculizumab is a monoclonal antibody that binds to C5 and
inhibits formation of the MAC. Eculizumab has largely
been studied in atypical hemolytic uremic syndrome.
Case reports utilizing eculizumab as part of a multimodal
treatment regimen for AMR have shown depletion of DSA
and improvement in allograft function (10,64), but no headto-head comparisons or clinical trials have been published
to date.
Long-term outcomes
Despite improvements in diagnosis, clinical outcomes after
AMR remain poor (39). Astor and colleagues reported
a case series of 40 patients who developed AMR and
found 1- and 5-year survival to be near 80% and 40%
respectively (46). Otani and colleagues presented a series
of 9 patients who received therapy for AMR in which
5/9 initially improved with therapy, but 7/9 eventually
developed CLAD and 6/9 (67%) died within 3 years of
diagnosis of AMR (4). Witt and colleagues reported a series
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of 21 patients who developed AMR of whom 6/21 died
of refractory AMR, and all 15 who improved eventually
developed CLAD (3). Overall, 15/21 (71%) patients died
during the study period and the median survival after the
diagnosis of AMR was 593 days (3). Aguilar and colleagues
reported a series of 73 cases of AMR and found a 30-day
mortality of 26% despite aggressive antibody depleting
treatment (52). Indeed, multiple reports have shown that
the inability to clear DSA and a diagnosis of AMR are
associated with increased risk of CLAD (3,4). These reports
suggest that although AMR may be a reversible cause of
acute graft dysfunction, there is a high incidence of CLAD
and poor long-term survival after AMR.
Sensitization prior to transplantation
The presence of HLA antibodies prior to transplantation
has been associated with variable outcomes. While some
reports found no difference in survival, acute rejection, or
BOS, others have shown decreased survival, decreased rates
of transplantation, prolonged waiting times, and increases
in post-transplant ventilator days, acute rejection, AMR,
and BOS (65-70). Notably, HLA class II antibodies have
been associated with worse outcomes (3,52,68). Brugiere
and colleagues found that patients with class II DSA had
significantly higher mortality and significantly lower
freedom from BOS (68). Descriptive studies by Witt et al.
and Aguilar et al. also noted an association between HLA
class II antibodies, especially HLA-DQ antibodies, and the
development of AMR (3,52). Notably, pro-inflammatory
cytokines have been shown to induce the expression of class
II HLA on pulmonary endothelial cells (26,27). Together,
these studies illustrate that endothelial cells are the focal
point of antibody-mediated injury.
Desensitization protocols have been implemented
for sensitized patients with variable success. Appel and
colleagues treated 12/35 (34%) sensitized patients with
peri-transplant IVIG and extracorporeal immunoadsorption
(ECI) and found a significant decrease in acute rejection
but no significant difference in survival or BOS (71). Snyder
and colleagues treated 18/114 (16%) sensitized patients
with a desensitization protocol including plasmapheresis,
methylprednisolone, bortezomib, rituximab, and
IVIG (72). Among the 9/18 (50%) treated patients who
went on to receive a transplant, they found a significant
decrease in HLA antibody with pretreatment MFI
5,000–10,000; however, they found no difference in
PRA, cPRA, or post-transplant survival (72). Tinckam
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and colleagues treated 146 patients with known DSA or
with PRA >30% with a desensitization protocol including
perioperative plasma exchange, IVIG, anti-thymocyte
globulin, and mycophenolic acid and compared them to
194 unsensitized controls (73). They found that treated,
sensitized recipients had significantly lower rates of acute
rejection compared with unsensitized controls and found
no significant difference in spirometry or 1-year graft
survival (73). Courtwright and colleagues reviewed 203
cases, 18 of whom had pretransplant DSA and were treated
with peri-transplant plasmapheresis, and found that
sensitized patients were more likely to require prolonged
mechanical ventilation and to have AMR (74). They found
no difference in mortality or CLAD-free survival between
groups (74). While some centers have shown success, small
sample size, varied protocols and immunosuppressive
regimens, and heterogenous patient populations make it
challenging to draw conclusions regarding the role and
impact of desensitization protocols.
Gaps in knowledge and future directions
Despite the advances in diagnostic criteria and treatment
modalities in AMR, significant gaps in knowledge
remain. The true incidence of AMR remains unknown
with prior reports describing widely variable incidence
from 4% to greater than 50% (3,37,75,76). The previous
lack of consensus diagnostic criteria and highly sensitive
assays for DSA may explain this variability. However, the
limitations of the current consensus diagnostic criteria
present further challenges in defining the true incidence
of AMR. In addition, chronic and subclinical AMR are illdefined, and the impact of these potential forms of rejection
on long-term outcomes remains unknown. The lack of
highly sensitive assays for non-HLA antibodies further
limits our understanding of AMR. While inability to clear
DSA is associated with CLAD and poor survival, the
associated mechanisms remain unclear, and protocols for
prevention and treatment have yet to be developed. Longterm outcomes after AMR are poor and data for specific
treatment protocols remain sparse. Large, multicenter,
randomized clinical trials are necessary to better define
the optimal treatment regimen. These studies need not
be placebo controlled as equipoise exists for head-to-head
comparisons of previously studied regimens. Furthermore,
dosing studies are necessary to identify the optimal doses
for treatment of AMR as current dosing strategies are
based on the use of agents in other medical conditions.
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Finally, as investigations of new diagnostic techniques and
treatment strategies emerge, large, multicenter studies will
be necessary to identify best-practices for implementation.
There are multiple areas of ongoing and future
investigation in AMR including in the areas of mechanisms,
diagnosis, and treatment. Li and colleagues developed
a mouse lung re-transplantation model of AMR and
found that tolerant allografts developed BALT and that
depletion of regulatory T-cells led to AMR (38). They
suggest a role for future investigation of the pathogenesis
of AMR utilizing this model and the treatment of AMR by
costimulatory blockade of T-cells and B-cells (38).
Given the limitations of the current consensus diagnostic
criteria for AMR, alternative methods for diagnosis are
actively being investigated including donor-derived cell-free
DNA (ddcfDNA) and transcriptome analyses. The presence
of injury in the allograft results in donor cell apoptosis and
circulation of donor DNA in the serum of recipients (77-80).
Assays have been developed that can quantify the amount
of ddcfDNA in recipient serum (77-81). This technique
involves sequencing DNA found in the serum of recipients
and differentiating and quantifying donor DNA (77,81).
These assays were found to have excellent sensitivity for
acute rejection, but specificity is poor (77-81). Notably,
Agbor-Enoh and colleagues found the sensitivity for AMR
to be approaching 100%, but specificity was only 35%;
however, when coupled with testing for DSA, specificity
improved to 90% (82,83). In addition, they found that
elevations in ddcfDNA preceded the clinical diagnosis of
AMR by a median of 2.8 months (82). Measurement of cellfree DNA could serve as a noninvasive method to diagnose
impending AMR; however, it is unclear if treatment of
impending AMR will improve outcomes. The Early
Detection and Treatment of AMR (eDATA) study proposes
to identify patients who have elevated ddcfDNA and
DSA and to initiate treatment prior to developing clinical
AMR. This study is currently in progress and will compare
outcomes with conventional diagnosis and treatment of
clinical AMR (83).
Another area of active investigation is transcriptome
analysis. Micro RNAs (miRNA) are short, noncoding RNA
sequences that regulate gene expression. Transcriptome
analysis can be performed on BAL cell pellets, peripheral
blood mononuclear cells, and biopsy specimens (84-88).
Early studies have shown that differential expression of
miRNAs correlate with episodes of acute rejection and
may even precede diagnosis of chronic rejection (84-88).
While early data for antibody associated chronic rejection
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exists (84), transcriptome analysis has yet to be evaluated in
the diagnosis of AMR.
Valenzuela and colleagues reviewed emerging therapies
for AMR that inhibit antibody formation and antibodymediated allograft injury by targeting CTLA4, IL-6
receptor, B-cell activating factor, C1, mTOR, and the
Fc region of bound antibody (40). Future studies should
evaluate the role of these alternate pathways of immune
modulation in AMR.
Conclusions
AMR generally results in severe acute allograft dysfunction
and is associated with increased risk of CLAD and poor
survival. Despite development of consensus diagnostic
criteria, treatment protocols have limited data and longterm outcomes remain poor. Promising diagnostic
techniques are actively being investigated that may allow
for early detection and treatment of AMR. Further research
is required to identify and define chronic and subclinical
AMR, and head-to-head comparisons of currently used
treatment protocols are necessary to identify an optimal
treatment approach. Gaps in knowledge regarding the
epidemiology, mechanisms, diagnosis, and treatment of
AMR persist and future research should focus on addressing
these gaps.
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